Yuan Shao-Ying, He Chao-Ba, Zhang Zhao-Lei, Wang Wei-Guang, Wang Wen, Liang Yi-Chun, Qin Zhan, Jin Ming-Yu, Wang You-Lian, Geng Li-Guo
Department of Andrology, Guangdong Hospital of Traditional Chinese Medicine, Zhuhai, Guangdong 510915, China.
The Second School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, China.
Zhonghua Nan Ke Xue. 2022 Dec;28(12):1113-1118.
To investigate the effect of pricking-reinforcing -reducing therapy (PRRT) on the semen quality and seminal plasma biochemical indexes of varicocele (VC) infertility patients.
We randomly and equally assigned 160 patients with VC infertility into a PRRT and a control group, the former treated by PRRT and the latter with oral ShengjingCapsules. Before and after treatment, we obtained the semen parameters, sperm morphology, sperm survival rate, sperm acrosin activity, seminal plasma neutral α glucosidase and seminal plasma zinc in the patients and compared them between the two groups.
Before treatment, there were no statistically significant differences between the PRRT and control groups in sperm concentration (［16.81 ± 7.83］ vs ［16.80 ± 7.54］ ×106 /ml, P > 0.05), total sperm count (［42.01 ± 19.57］ vs ［41.99 ± 18.84］ ×106, P > 0.05), percentages of progressively motile sperm (PMS) (［15.37 ± 11.03］% vs ［14.68 ± 10.27］%, P > 0.05) and morphologically normal sperm ( MNS) (1.62 ± 1.51］% vs ［1.62 ± 1.13］%, P > 0.05), sperm survival rate (［28.11 ± 18.95］% vs ［28.23±18.38］%, P > 0.05) and sperm acrosin activity (［28.11 ± 14.64］ vs ［27.19 ± 14.07］ U/L, P > 0.05). After three months of treatment, all the patients showed evident increases in the above parameters (P < 0.05), even higher in the PRRT than in the control group, more significantly in sperm concentration (［38.88 ± 30.54］ vs ［25.60 ± 14.71］ ×106 /ml, P < 0.05), PMS (［32.60 ± 12.46］% vs ［27.67 ± 12.27］%, P < 0.05) and sperm acrosin activity (［65.74±31.81］ vs ［67.94±17.95］ U/L, P < 0.05), though not significantly in total sperm count (97.20 ± 76.35］ vs ［88.19 ± 39.56］ ×106, P > 0.05), MNS (［2.35 ± 1.83］% vs ［1.87 ± 1.20］%, P > 0.05) and sperm survival rate (［61.44 ± 20.02］% vs ［59.12 ± 22.48］%, P > 0.05). Compared with the baseline, after treatment, the patients in the PRRT group also exhibited elevated levels of neutral α-glucosidase (［14.42 ± 5.90］ vs ［28.43 ± 19.76］ U/L, P < 0.05) and seminal plasma zinc (［2.11 ± 1.22］ vs ［2.89 ± 1.23］ mmol/L, P < 0.05), and so did the controls (［14.44 ± 5.61］ vs ［26.66 ± 17.69］ U/L , P < 0.05) and (［2.09 ± 1.10］ vs ［2.82±1.08］ mmol/L, P < 0.05). No statistically significant difference, however, was observed between the two groups after treatment (P > 0.05).
PRRT can significantly improve semen quality in patients with VC infertility, even more effective than ShengjingCapsules in improving sperm concentration, PMS, sperm survival rate, and sperm acrosin activity, which may be related to its effect of elevating the levels of seminal plasma neutral-α glucosidase and zinc providing sufficient energy for basic sperm metabolism, maturation, energy acquisition and motility.
探讨针刺补泻疗法（PRRT）对精索静脉曲张（VC）不育患者精液质量及精浆生化指标的影响。
将160例VC不育患者随机等分为PRRT组和对照组，前者采用PRRT治疗，后者口服生精胶囊。治疗前后，获取患者的精液参数、精子形态、精子存活率、精子顶体酶活性、精浆中性α-葡萄糖苷酶和精浆锌，并对两组进行比较。
治疗前，PRRT组与对照组在精子浓度（［16.81±7.83］对［16.80±7.54］×10⁶/ml，P>0.05）、精子总数（［42.01±19.57］对［41.99±18.84］×10⁶，P>0.05）、前向运动精子百分比（PMS）（［15.37±11.03］%对［14.68±10.27］%，P>0.05）和形态正常精子百分比（MNS）（［1.62±1.51］%对［1.62±1.13］%，P>0.05）、精子存活率（［28.11±18.95］%对［28.23±18.38］%，P>0.05）及精子顶体酶活性（［28.11±14.64］对［27.19±14.07］U/L，P>0.05）方面均无统计学差异。治疗3个月后，所有患者上述参数均显著升高（P<0.05），PRRT组升高幅度高于对照组，精子浓度（［38.88±30.54］对［25.60±14.71］×10⁶/ml，P<0.05）、PMS（［32.60±12.46］%对［27.67±12.27］%，P<0.05）及精子顶体酶活性（［65.74±31.81］对［67.94±17.95］U/L，P<0.05）升高更显著，而精子总数（［97.20±76.35］对［88.19±39.56］×10⁶，P>0.05）、MNS（［2.35±1.83］%对［1.87±1.20］%，P>0.05）及精子存活率（［61.44±20.02］%对［59.12±22.48］%，P>0.05）升高不显著。与基线相比，治疗后PRRT组患者精浆中性α-葡萄糖苷酶（［14.42±5.90］对［28.43±19.76］U/L，P<0.05）和精浆锌（［2.11±1.22］对［2.89±1.23］mmol/L，P<0.05）水平升高，对照组患者也如此（［14.44±5.61］对［26.66±17.69］U/L，P<0.05）及（［2.09±1.10］对［2.82±1.08］mmol/L，P<0.05）。然而，治疗后两组间无统计学差异（P>0.05）。
PRRT可显著改善VC不育患者的精液质量，在提高精子浓度、PMS、精子存活率及精子顶体酶活性方面比生精胶囊更有效，这可能与其升高精浆中性α-葡萄糖苷酶和锌水平、为精子基本代谢、成熟、能量获取及运动提供充足能量的作用有关。
Zotero 插件